References
Allison SE, Chen Y, Petrovic N, Zhang J, Bourget K, Mackenzie PI,
et al. (2017). Activation of ALDH1A1 in MDA-MB-468 breast cancer cells
that over-express CYP2J2 protects against paclitaxel-dependent cell
death mediated by reactive oxygen species. Biochem Pharmacol
143: 79-89.
Blom JW, Doggen CJ, Osanto S, & Rosendaal FR (2005). Malignancies,
prothrombotic mutations, and the risk of venous thrombosis. Jama
293: 715-722.
Burotto M, Manasanch EE, Wilkerson J, & Fojo T (2015). Gefitinib and
erlotinib in metastatic non-small cell lung cancer: a meta-analysis of
toxicity and efficacy of randomized clinical trials. Oncologist
20: 400-410.
Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, et al. (2013).
Sunitinib versus sorafenib in advanced hepatocellular cancer: results of
a randomized phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 31:4067-4075.
Cheong EJ, Goh JJ, Hong Y, Venkatesan G, Liu Y, Chiu GN, et al.(2017). Application of Static Modeling –in the Prediction of In Vivo
Drug-Drug Interactions between Rivaroxaban and Antiarrhythmic Agents
Based on In Vitro Inhibition Studies. Drug Metab Dispos 45:260-268.
Das A, Weigle AT, Arnold WR, Kim JS, Carnevale LN, & Huff HC (2020).
CYP2J2 Molecular Recognition: A New Axis for Therapeutic Design.
Pharmacol Ther 215: 107601.
Dhillon S (2015). Gefitinib: a review of its use in adults with advanced
non-small cell lung cancer. Target Oncol 10: 153-170.
Douketis JD, Crowther MA, Foster GA, & Ginsberg JS (2001). Does the
location of thrombosis determine the risk of disease recurrence in
patients with proximal deep vein thrombosis? Am J Med 110:515-519.
Fahmi OA, Maurer TS, Kish M, Cardenas E, Boldt S, & Nettleton D (2008).
A combined model for predicting CYP3A4 clinical net drug-drug
interaction based on CYP3A4 inhibition, inactivation, and induction
determined in vitro. Drug Metab Dispos 36: 1698-1708.
Guilhot F (2004). Indications for imatinib mesylate therapy and clinical
management. Oncologist 9: 271-281.
Isoherranen N, Lutz JD, Chung SP, Hachad H, Levy RH, &
Ragueneau-Majlessi I (2012). Importance of multi-p450 inhibition in
drug-drug interactions: evaluation of incidence, inhibition magnitude,
and prediction from in vitro data. Chem Res Toxicol 25:2285-2300.
January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC,
Jr., et al. (2019). 2019 AHA/ACC/HRS Focused Update of the 2014
AHA/ACC/HRS Guideline for the Management of Patients With Atrial
Fibrillation: A Report of the American College of Cardiology/American
Heart Association Task Force on Clinical Practice Guidelines and the
Heart Rhythm Society in Collaboration With the Society of Thoracic
Surgeons. Circulation 140: e125-e151.
Kalgutkar AS, Obach RS, & Maurer TS (2007). Mechanism-based
inactivation of cytochrome P450 enzymes: chemical mechanisms,
structure-activity relationships and relationship to clinical drug-drug
interactions and idiosyncratic adverse drug reactions. Curr Drug Metab
8: 407-447.
Kalra S, Rini BI, & Jonasch E (2015). Alternate sunitinib schedules in
patients with metastatic renal cell carcinoma. Ann Oncol 26:1300-1304.
Karkhanis A, Hong Y, & Chan ECY (2017). Inhibition and inactivation of
human CYP2J2: Implications in cardiac pathophysiology and opportunities
in cancer therapy. Biochem Pharmacol 135: 12-21.
Kuczynski EA, Lee CR, Man S, Chen E, & Kerbel RS (2015). Effects of
Sorafenib Dose on Acquired Reversible Resistance and Toxicity in
Hepatocellular Carcinoma. Cancer Res 75: 2510-2519.
Lau CL, Chan ST, Selvaratanam M, Khoo HW, Lim AY, Modamio P, et
al. (2015). Sunitinib-ibuprofen drug interaction affects the
pharmacokinetics and tissue distribution of sunitinib to brain, liver,
and kidney in male and female mice differently. Fundamental & clinical
pharmacology 29: 404-416.
Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth
R, et al. (1999). Rates of initial and recurrent thromboembolic
disease among patients with malignancy versus those without malignancy.
Risk analysis using Medicare claims data. Medicine (Baltimore)
78: 285-291.
Li JN, Cao YF, He RR, Ge GB, Guo B, & Wu JJ (2018). Evidence for
Shikonin acting as an active inhibitor of human carboxylesterases 2:
Implications for herb-drug combination. Phytother Res 32:1311-1319.
Michaud V, Frappier M, Dumas MC, & Turgeon J (2010). Metabolic activity
and mRNA levels of human cardiac CYP450s involved in drug metabolism.
PLoS One 5: e15666.
Monreal M, Falgá C, Valdés M, Suárez C, Gabriel F, Tolosa C, et
al. (2006). Fatal pulmonary embolism and fatal bleeding in cancer
patients with venous thromboembolism: findings from the RIETE registry.
J Thromb Haemost 4: 1950-1956.
Nebot N, Crettol S, d’Esposito F, Tattam B, Hibbs DE, & Murray M
(2010). Participation of CYP2C8 and CYP3A4 in the N-demethylation of
imatinib in human hepatic microsomes. Br J Pharmacol 161:1059-1069.
Ning J, Liu T, Dong P, Wang W, Ge G, Wang B, et al. (2019).
Molecular Design Strategy to Construct the Near-Infrared Fluorescent
Probe for Selectively Sensing Human Cytochrome P450 2J2. J Am Chem Soc
141: 1126-1134.
O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes
F, et al. (2003). Imatinib compared with interferon and low-dose
cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N
Engl J Med 348: 994-1004.
Onaitis M, D’Amico T, Zhao Y, O’Brien S, & Harpole D (2010). Risk
factors for atrial fibrillation after lung cancer surgery: analysis of
the Society of Thoracic Surgeons general thoracic surgery database. Ann
Thorac Surg 90: 368-374.
Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami
B, et al. (2002). Recurrent venous thromboembolism and bleeding
complications during anticoagulant treatment in patients with cancer and
venous thrombosis. Blood 100: 3484-3488.
Saliba W, Rennert HS, Gronich N, Gruber SB, & Rennert G (2018).
Association of atrial fibrillation and cancer: Analysis from two large
population-based case-control studies. PLoS One 13: e0190324.
Scheffler M, Di Gion P, Doroshyenko O, Wolf J, & Fuhr U (2011).
Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on
4-anilinoquinazolines. Clin Pharmacokinet 50: 371-403.
Shalhoub J, Norrie J, Baker C, Bradbury AW, Dhillon K, Everington
T, et al. (2017). Graduated Compression Stockings as an Adjunct
to Low Dose Low Molecular Weight Heparin in Venous Thromboembolism
Prevention in Surgery: A Multicentre Randomised Controlled Trial. Eur J
Vasc Endovasc Surg 53: 880-885.
Song AB, Rosovsky RP, Connors JM, & Al-Samkari H (2019). Direct oral
anticoagulants for treatment and prevention of venous thromboembolism in
cancer patients. Vascular health and risk management 15:175-186.
Streiff MB (2016). Thrombosis in the setting of cancer. Hematology Am
Soc Hematol Educ Program 2016: 196-205.
Streiff MB, Holmstrom B, Angelini D, Ashrani A, Bockenstedt PL, Chesney
C, et al. (2020). NCCN Guidelines Insights: Cancer-Associated
Venous Thromboembolic Disease, Version 1.2020. J Natl Compr Canc Netw
16: 1289-1303.
Timp JF, Braekkan SK, Versteeg HH, & Cannegieter SC (2013).
Epidemiology of cancer-associated venous thrombosis. Blood 122:1712-1723.
Tirumani SH, Jagannathan JP, Krajewski KM, Shinagare AB, Jacene H, &
Ramaiya NH (2013). Imatinib and beyond in gastrointestinal stromal
tumors: A radiologist’s perspective. AJR Am J Roentgenol 201:801-810.
von Mehren M, & Widmer N (2011). Correlations between imatinib
pharmacokinetics, pharmacodynamics, adherence, and clinical response in
advanced metastatic gastrointestinal stromal tumor (GIST): an emerging
role for drug blood level testing? Cancer Treat Rev 37:291-299.
Wertheimer C, Siedlecki J, Kook D, Mayer WJ, Wolf A, Klingenstein
A, et al. (2015). EGFR inhibitor Gefitinib attenuates posterior
capsule opacification in vitro and in the ex vivo human capsular bag
model. Graefes Arch Clin Exp Ophthalmol 253: 409-417.
Witt DM, Nieuwlaat R, Clark NP, Ansell J, Holbrook A, Skov J, et
al. (2018). American Society of Hematology 2018 guidelines for
management of venous thromboembolism: optimal management of
anticoagulation therapy. Blood advances 2: 3257-3291.
Wu S, Moomaw CR, Tomer KB, Falck JR, & Zeldin DC (1996). Molecular
cloning and expression of CYP2J2, a human cytochrome P450 arachidonic
acid epoxygenase highly expressed in heart. J Biol Chem 271:3460-3468.
Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R,
Galderisi M, et al. (2016). 2016 ESC Position Paper on cancer
treatments and cardiovascular toxicity developed under the auspices of
the ESC Committee for Practice Guidelines: The Task Force for cancer
treatments and cardiovascular toxicity of the European Society of
Cardiology (ESC). Eur Heart J 37: 2768-2801.
Zanger UM, & Schwab M (2013). Cytochrome P450 enzymes in drug
metabolism: regulation of gene expression, enzyme activities, and impact
of genetic variation. Pharmacol Ther 138: 103-141.
Zhao T, Chen Y, Wang D, Wang L, Dong P, Zhao S, et al. (2021).
Identifying the Dominant Contribution of Human Cytochrome P450 2J2 to
the Metabolism of Rivaroxaban, an Oral Anticoagulant. Cardiovasc Drugs
Ther.